1-5 of 5
Patrick J. Flynn
Close
Sort by
Journal Articles

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Clinical Trials & Observations
Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo E. Bordoni, Vivian J. M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert Chen, Abraham Fong, Yinghui Wang, Christopher A. Yasenchak
Journal: Blood
Blood (2017) 130 (26): 2829–2837.
https://doi.org/10.1182/blood-2017-06-787200
Published: 2017
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study

Christopher A. Yasenchak, MD, Andres Forero-Torres, Vivian Jean Mikao Cline-Burkhardt, Rodolfo E Bordoni, MD, Dipti Patel-Donnelly, MD, Patrick J. Flynn, MD, Robert Chen, Abraham Fong, Jonathan W. Friedberg, MD MMSc
Journal: Blood
Blood (2015) 126 (23): 587.
https://doi.org/10.1182/blood.V126.23.587.587
Published: 2015
Journal Articles

PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

Ivana N. Micallef, MD, Matthew J. Maurer, Thomas E. Witzig, MD, Daniel Nikcevich, MD, PhD, Paul Kurtin, MD, Michael W. Cannon, MD, Patrick J. Flynn, MD, Gamini S. Soori, MD, Val Lowe, MD, Gregory Wiseman, MD
Journal: Blood
Blood (2009) 114 (22): 137.
https://doi.org/10.1182/blood.V114.22.137.137
Published: 2009
Journal Articles

A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma.

Shaji Kumar, MD, Patrick J. Flynn, MD, Wee Joo J Chng, MD, Kenny Ieng Kit Lei, MD, FRCP, Jacob Allred, Kristina Laumann, Kevin Webster, Morie A Gertz, MD, Angela Dispenzieri, MD, Philip R. Greipp, MD, Suzanne R. Hayman, MD, Steven R. Zeldenrust, M.D., Ph.D., Charles Erlichman, MD, S. Vincent Rajkumar, MD, Martha Q. Lacy, MD
Journal: Blood
Blood (2009) 114 (22): 4954.
https://doi.org/10.1182/blood.V114.22.4954.4954
Published: 2009
Journal Articles

Results of a Nonrandomized, Open-Label, Phase II Study of Combined Gemcitabine, Mitoxantrone, and Rituximab in Relapsed or Refractory Mantle Cell Lymphoma.

Lawrence E. Garbo, MD, Patrick J. Flynn, MD, Margaret A. MacRae, MD, Mary A. Rauch, BS, Yunfei Wang, MS, Kathryn S. Kolibaba, MD
Journal: Blood
Blood (2007) 110 (11): 4452.
https://doi.org/10.1182/blood.V110.11.4452.4452
Published: 2007